#Biktarvy

The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.

The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.

This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.

More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.

Biktarvy has a lower rate of adverse health events, according to 96-week data.

Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.

The new single-tablet antiretroviral regimen includes the integrase inhibitor bictegravir and is the smallest such tablet on the market.

The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.